Translational stroke research of the combination of thrombolysis and antioxidant therapy

Stroke

Volumn 42, Issue 5, 2011, Pages 1495-1499

  Amaro, Sergio ^a   Chamorro, Angel ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

acute stroke; clinical trials; neuroprotection; thrombolysis

Indexed keywords

ALTEPLASE; ANTIOXIDANT; BIOLOGICAL MARKER; DISUFENTON SODIUM; FIBRINOLYTIC AGENT; NITRONE DERIVATIVE; NORPHENAZONE; URIC ACID;

ARTICLE; BLOOD CLOT LYSIS; DRUG EFFICACY; NEUROPROTECTION; OXIDATIVE STRESS; PRIORITY JOURNAL; RECANALIZATION; REPERFUSION INJURY; STROKE; TRANSLATIONAL RESEARCH;

ANTIOXIDANTS; ANTIPYRINE; BIOLOGICAL MARKERS; FIBRINOLYTIC AGENTS; HUMANS; NITROGEN OXIDES; OXIDATIVE STRESS; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; URIC ACID;

EID: 79955482316     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.615039     Document Type: Article

References (48)

1. Demaerschalk BM, Hwang HM, Leung G. US cost burden of ischemic stroke: a systematic literature review. Am J Manag Care. 2010;16: 525-533.
2. Wardlaw JM, Murray V, Berge E, del Zoppo GJ. Thrombolysis for acute ischemic stroke. Cochrane Database Syst Rev. 2009;4:CD000213.
3. Bluhmki E, Chamorro A, Dávalos A, Machnig T, Sauce C, Wahlgren N, et al. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol. 2009;8:1095-1102.
4. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375:1695-1703.
5. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1026 experimental treatments in acute stroke. Ann Neurol. 2006;59:467-477. (Pubitemid 43358067)
6. Ly JV, Zavala JA, Donnan GA. Neuroprotection and thrombolysis: com-bination therapy in acute ischemic stroke. Expert Opin Pharmacother. 2006;7:1571-1581. (Pubitemid 44209601)
7. Kassem-Moussa H, Graffagnino C. Nonocclusion and spontaneous re-canalization rates in acute ischemic stroke: a review of cerebral angiography studies. Arch Neurol. 2002;59:1870-1873. (Pubitemid 35424643)
8. Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke. 2007;38:967-973. (Pubitemid 46568460)
9. Lee M, Hong KS, Saver JL. Efficacy of intra-arterial fibrinolysis for acute ischemic stroke: meta-analysis of randomized controlled trials. Stroke. 2010;41:932-937.
10. Janardhan V, Qureshi AI. Mechanisms of ischemic brain injury. Curr Cardiol Rep. 2004;6:117-123. (Pubitemid 38906902)
11. Schaller B, Graf R. Cerebral ischemia and reperfusion: the pathophysi-ologic concept as a basis for clinical therapy. J Cereb Blood Flow Metab. 2004;24:351-371. (Pubitemid 38452228)
12. Kidwell CS, Saver JL, Mattiello J, Starkman S, Vinuela F, Duckwiler G, et al. Diffusion-perfusion MRI characterization of post-recanalization hyperperfusion in humans. Neurology. 2001;57:2015-2021. (Pubitemid 33126868)
13. Flamm ES, Demopoulos HB, Seligman ML, Poser RG, Ransohoff J. Free radicals in cerebral ischemia. Stroke. 1978;9:445-447. (Pubitemid 8389070)
14. Kinuta Y, Kikuchi H, Ishikawa M, Kimura M, Itokawa Y. Lipid peroxi-dation in focal cerebral ischemia. J Neurosurg. 1989;71:421-429. (Pubitemid 19225556)
15. Crack PJ, Taylor JM. Reactive oxygen species and the modulation of stroke. Free Radic Biol Med. 2005;38:1433-1444. (Pubitemid 40693828)
16. Liu KJ, Rosenberg G. Matrix metalloproteinases and free radicals in cerebral ischemia. Free Radic Biol Med. 2005;39:71-80. (Pubitemid 40733117)
17. Harston GW, Sutherland BA, Kennedy J, Buchan AM. The contribution of L-arginine to the neurotoxicity of recombinant tissue plasminogen activator following cerebral ischemia: a review of rtPA neurotoxicity. J Cereb Blood Flow Metab. 2010;30:1804-1816.
18. Matys T, Strickland S. Tissue plasminogen activator and NMDA receptor cleavage. Nat Med. 2003;9:371-372.
19. Su EJ, Fredriksson L, Geyer M, Folestad E, Cale J, Andrae J, et al. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med. 2008;14: 731-737.
20. Saenger AK, Christenson RH. Stroke biomarkers: progress and chal-lenges for diagnosis, prognosis, differentiation, and treatment. Clin Chem. 2010;56:21-33.
21. Jauch EC, Lindsell C, Broderick J, Fagan SC, Tilley BC, Levine SR; NINDS rt-PA Stroke Study Group. Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study. Stroke. 2006;37:2508-2513. (Pubitemid 44454670)
22. Ning M, Furie KL, Koroshetz WJ, Lee H, Barron M, Lederer M, et al. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke. Neurology. 2006;66:1550-1555. (Pubitemid 43958553)
23. Domínguez C, Delgado P, Vilches A, Martín-Gallán P, Ribó M, Sant-amarina E, et al. Oxidative stress after thrombolysis-induced reperfusion in human stroke. Stroke. 2010;41:653-660.
24. Kelly PJ, Morrow JD, Ning M, Koroshetz W, Lo EH, Terry E, et al. Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke: the Biomarker Evaluation for Antioxidant Therapies in Stroke (BEAT-Stroke) study. Stroke. 2008;39:100-104.
25. Whiteley W, Chong WL, Sengupta A, Sandercock P. Blood markers for the prognosis of ischemic stroke: a systematic review. Stroke. 2009;40: e380-e389.
26. Feuerstein GZ, Zaleska MM, Krams M, Wang X, Day M, Rutkowski JL, et al. Missing steps in the STAIR case: a Translational Medicine per-spective on the development of NXY-059 for treatment of acute ischemic stroke. J Cereb Blood Flow Metab. 2008;28:217-219.
27. Barr TL, Latour LL, Lee KY, Schaewe TJ, Luby M, Chang GS, et al. Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9. Stroke. 2010;41:e123-e128.
28. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, et al. Matrix metalloproteinase-9 pretreatment level predicts intra-cranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003;107:598-603. (Pubitemid 36176811)
29. Rosell A, Alvarez-Sabín J, Arenillas JF, Rovira A, Delgado P, Fernández-Cadenas I, et al. A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke. Stroke. 2005;36:1415-1420. (Pubitemid 40967504)
30. Amaro S, Obach V, Cervera A, Urra X, Gómez-Choco M, Planas AM, et al. Course of matrix metalloproteinase-9 isoforms after the administration of uric acid in patients with acute stroke: a proof-of-concept study. J Neurol. 2009;256:651-656.
31. Margaill I, Plotkine M, Lerouet D. Antioxidant strategies in the treatment of stroke. Free Radic Biol Med. 2005;39:429-443. (Pubitemid 41021642)
32. Lapchak PA, Araujo DM, Song D, Wei J, Zivin JA. Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino) methyl]benzene-1,3- disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke. 2002;33:1411-1415. (Pubitemid 34517068)
33. Diener HC, Lees KR, Lyden P, Grotta J, Dávalos A, Davis SM, et al. SAINT I and II Investigators. NXY-059 for the treatment of acute stroke: pooled analysis ofthe SAINT I and IITrials. Stroke. 2008;39:1751-1758.
34. Maples KR, Ma F, Zhang YK, Comparison of the radical trapping ability of PBN, S-PBN and NXY-059. Free Radic Res. 2001;34:417-426. (Pubitemid 32331666)
35. Ginsberg MD, Becker DA, Busto R, Belayev A, Zhang YB, Khoutorova L, et al. Stilbazulenyl nitrone, a novel antioxidant, is highly neuropro-tective in focal ischemia. Ann Neurol. 2003;54:330-342. (Pubitemid 37072035)
36. Sun Y, Jiang J, Zhang Z, Yu P, Wang L, Xu C, et al. Antioxidative and thrombolytic TMP nitrone for treatment of ischemic stroke. Bioorg Med Chem. 2008;16:8868-8874.
37. Lapchak PA. A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? Expert Opin Pharmacother. 2010;11:1753-1763.
38. Lapchak PA, Zivin JA. The lipophilic multifunctional antioxidant edaravone (Radicut) improves behavior following embolic strokes in rabbits: a combination therapy study with tissue plasminogen activator. Exp Neurol. 2009;215:95-100.
39. Isahaya K, Yamada K, Yamatoku M, Sakurai K, Takaishi S, Kato B, et al. Effects of edaravone, a free radical scavenger, on serum levels of inflammatory biomarkers in acute brain infarction. J Stroke Cerebrovasc Dis. 2011 Jan 5 [Epub ahead of print].
40. Yoshifumi T. Benefits of Pre-treatment with edaravone in tPA intrave-nous therapy for acute cerebral infarction. XXIII International Sym-posium on Cerebral Blood Flow. J Cereb Blood Flow Metab. 2007;Suppl 1:BP34-06M.
41. Amaro S, Planas AM, Chamorro A. Uric acid administration in patients with acute stroke: a novel approach to neuroprotection. Expert Rev Neu-rother. 2008;8:259-270. (Pubitemid 351281113)
42. Yu ZF, Bruce-Keller AJ, Goodman Y, Mattson MP. Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J Neurosci Res. 1998;53: 613-625. (Pubitemid 28380802)
43. Romanos E, Planas AM, Amaro S, Chamorro A. Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thrombo-embolic stroke. J Cereb Blood Flow Metab. 2007;27:14-20. (Pubitemid 46006580)
44. Amaro S, Soy D, Obach V, Cervera A, Planas AM, Chamorro A. A pilot study of dual treatment with recombinant tissue plasminogen activator and uric acid in acute ischemic stroke. Stroke. 2007;38:2173-2175. (Pubitemid 47012285)
45. Hong JM, Bang OY, Chung CS, Joo IS, Gwag BJ, Ovbiagele B. Influence of recanalization on uric acid patterns in acute ischemic stroke. Cere-brovasc Dis. 2010;29:431-439.
46. Chamorro A, Obach V, Cervera A, Revilla M, Deulofeu R, Aponte JH. Prognostic significance of uric acid serum concentration in patients with acute ischemic stroke. Stroke. 2002;33:1048-1452.
47. Amaro S, Urra X, Gómez-Choco M, Obach V, Cervera A, Vargas M, et al. Uric acid levels are relevant in patients with stroke treated with thrombolysis. Stroke. 2011;42(suppl 1):S28-S32.
48. Amaro S, Cánovas D, Castellanos M, Gállego J, Martí-Fàbregas J, Segura T, et al. The URICO-ICTUS study, a phase 3 study of combined treatment with uric acid and rtPA administered intravenously in acute ischemic stroke patients within the first 4.5 h of onset of symptoms. Int J Stroke. 2010;5:325-328.